Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Ablative Radiotherapy (SABR) for Refractory Ventricular Tachycardia - a Phase I/II Study

NCT03349892 is registered in ClinicalTrials.gov with University of California, Los Angeles as lead sponsor.

NCT NCT03349892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03349892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Ablative Radiotherapy (SABR) for Refractory Ventricular Tachycardia - a Phase I/II Study
Lead sponsor
University of California, Los Angeles
Phase
Not applicable
Overall status
Completed
Start date
April 1, 2017
Completion date
August 6, 2019
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory ventricular tachycardia